Generated August 9, 2026.
Overview
ARKG and XBI both target the biotech and genomics space but follow opposing philosophies. ARKG is an actively managed ETF that concentrates on genomics, gene editing, and molecular diagnostics companies, while XBI is a passively managed equal-weight tracker of the S&P Biotechnology Select Industry Index covering the broader biotech sector. The key distinction: ARKG bets on manager conviction in disruptive genomics names; XBI aims for low-cost broad biotech exposure with mechanical rebalancing.
How they differ
ARKG's active strategy and genomics-specific focus create substantially higher volatility—its beta of 2.38 versus XBI's 1.14 reflects both the concentrated thesis and the leverage implicit in active positioning. ARKG's expense ratio of 0.75% is more than double XBI's 0.35%, a meaningful drag on long-term returns for equivalent performance. XBI's equal-weight methodology rebalances quarterly, ensuring no single holding dominates, whereas ARKG's conviction-driven picks can build large positions in high-conviction names. XBI's $9.96B in assets dwarfs ARKG's $1.65B, giving it deeper liquidity and lower trading costs; ARKG distributes annually while XBI pays quarterly, affecting reinvestment timing and tax-loss harvesting flexibility.
Who each is best for
ARKG: Fits investors with high risk tolerance, a long time horizon, and conviction that genomics disruption will outperform the broader biotech sector. Works for those comfortable with concentrated bets on CRISPR, gene therapy, and molecular diagnostics and who accept the volatility that active management in this space typically brings.
XBI: Fits investors seeking broad, low-cost biotech exposure without manager selection risk. Designed for those prioritizing simplicity, liquidity, and steady quarterly income over the potential upside of targeted genomics plays.
Key risks to know
- Genomics concentration risk (ARKG): The fund's focus on genomics, CRISPR, and gene editing creates meaningful single-theme exposure. If these technologies face regulatory setbacks or delayed commercialization, the portfolio could underperform the broader biotech index significantly.
- Volatility and drawdown risk (ARKG): A beta of 2.38 means ARKG amplifies biotech sector moves in both directions. During biotech downturns, the fund is likely to decline roughly 2.4× as much as the market, potentially eroding capital faster than a diversified holding.
- Active management performance risk (ARKG): The 0.75% expense ratio is paid regardless of outperformance. If the active strategy underperforms the broader index after fees over multi-year periods, the cost becomes a significant drag.
- Equal-weight rebalancing drag (XBI): XBI's equal-weight methodology forces periodic selling of winners and buying of losers. In a prolonged bull market for large-cap biotech names, this mechanical rebalancing may cap upside relative to market-cap weighting.
- Sector-level cyclicality (both): Biotech valuations are sensitive to FDA approval flows, clinical trial outcomes, and regulatory environment shifts. Both funds experience sharp drawdowns during sector dislocations independent of overall market conditions.
Bottom line
If you believe genomics will reshape medicine and can tolerate 2× market volatility to capture upside, ARKG's active focus offers concentrated exposure; if you want broad biotech at minimal cost with quarterly income and lower volatility, XBI's index approach is more straightforward. Past performance does not guarantee future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
